GILD

166.4300.06%
DP

Daniel Patrick O'Day

Chairman & CEO

Mr. Daniel Patrick O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galapagos NV since October 22, 2019 until April 2022. He served as Non-Independent Director at Galapagos NV since October 22, 2019 until April 28, 2020. Mr. O'Day has been the Chairman and Chief Executive Officer of Gilead Sciences, Inc. since March 01, 2019 and serves as its Director since March 1, 2019. He joined Gilead Sciences in March 2019. He serves on the Board of Directors for the Pharmaceutical Research and Manufacturers of America organization. Mr. O'Day was an Executive of Roche Holding AG since December 31, 2018 until February 2019. Mr. O'Day served as the Chief Executive Officer of Roche Pharmaceuticals at Roche Holding AG since June 3, 2016 until December 31, 2018. Mr. O'Day served as the Chief Operating Officer of Roche Pharma AG since September 1, 2012 until June 3, 2016. Mr. O'Day served as the Chief Operating Officer of Roche Diagnostics GmbH at Hoffmann-La Roche Ltd from 2010 to 2012. He has operating expertise at Roche. He served as the Chief Executive Officer and President of Roche Molecular Diagnostics USA at Roche Carolina Inc. and Roche Holding AG from 2006 to 2010. He served as the Chief Executive Officer and President of Roche Diagnostics GmbH. He began his career in 1987 at Roche in the U.S. Pharmaceuticals organization in Sales and Marketing. Afterwards, he held various positions in Roche Pharma in Switzerland, Japan and Denmark. He served as Director of Human Resources at Roche Pharma U.S.A. since 1995. He served as Director of Product Marketing at Roche Pharma U.S.A. since 1996. He served as Business Unit Head of Arthritis and Respiratory, Roche Pharma Headquarters since 1998. He served as Lifecycle Leader Tamiflu, Roche Pharma Headquarters since 1999. He served as Head of Corporate Planning at Nippon Roche K.K. since 2001. In 2006, Mr. O'Day joined Roche Diagnostics and became Head of the Business Area Molecular Diagnostics. Since January 1, 2010, he served as Chief Operating Officer for Roche's global diagnostics business. He worked many years managing international assignments that included life cycle leadership at Roche Pharmaceuticals in Basel, Switzerland; strategic planning and involvement in the Chugai merger in Tokyo, Japan; and prior to joining the molecular diagnostics unit, served as General Manager of Roche Pharmaceuticals in Denmark since 2003. He was a Director of Chugai Pharmaceutical Co. Ltd. since March 27, 2013 until February 2019. He has been a Director of Flatiron Health, Inc. since January 11, 2016 and Foundation Medicine, Inc. since April 2015. He served on the Board of Directors of Genentech USA, Inc. from August 2012 to December 2013 and Roche Diagnostics GmbH from January 2010 to November 2012. He served as a Director of Genentech, Inc. since 2012 until April 28, 2020 and served as its Member of Supervisory Board since April 28, 2020. He serves as Director at Shanghai Roche Pharmaceuticals Ltd. and California Life Sciences Association (also known as California Healthcare Institute). Mr. O'Day holds an BS in Biology from Georgetown University and a Master of Business Administration from Columbia University.

Positions